
PROMISS Diagnostics: Unleashing diagnostic potential with noninvasive cancer screening tests.
Founded with a mission to revolutionize cancer diagnostics, PROMISS Diagnostics focuses on providing globally accessible, non-invasive, and precise diagnostic tests for ovarian cancer. By integrating basic science with advanced analytics, the company aims to unlock significant diagnostic potential from common blood tests. Their core product is a noninvasive cancer screening test designed to detect ovarian cancer early, addressing a critical need in women's health.
PROMISS Diagnostics boasts a team of experts and a board of directors with extensive experience in oncology and diagnostics. The company has garnered attention from notable investors in the healthcare sector, contributing to its rapid growth and innovation. Key achievements include the development of their proprietary diagnostic technology, which has the potential to save countless lives by enabling earlier detection of ovarian cancer. Their impact is marked by a commitment to improving cancer outcomes through early detection and accessible testing solutions.

Avant Diagnostics

Prompt Diagnostics
prompt-dx.com

Pharus Diagnostics
pharusdx.com

Predictive Health Diagnostics Company

Empowered Diagnostics

Torpedo Diagnostics

Early Detection
cancer.us

Precipio
precipiodx.com

Stage I Diagnostics

Eventus Diagnostics

Cleveland Diagnostics
clevelanddx.com

Acuamark Diagnostics
acuamarkdx.com

Exact Sciences
exactsciences.com

Gregor Diagnostics

Urology Diagnostics
Companies similar to Promiss Diagnostics include Avant Diagnostics, Prompt Diagnostics, Pharus Diagnostics and Predictive Health Diagnostics Company.
Promiss Diagnostics was founded in 2017.
Promiss Diagnostics' headquarters is located in Wauwatosa, WI, US.
Promiss Diagnostics' most recent funding round was for $400k (USD) in January 2020.
As of Jan 10, 2020, Promiss Diagnostics has raised a total of $400k (USD).
Promiss Diagnostics has 5 employees as of Feb 5, 2024.